Medline (MDLN) Q4 Net Sales Rise 14.8% to $7.8B Following Completion of IPO

Medline Inc. (NASDAQ:MDLN) is one of the best NASDAQ stocks to buy according to hedge funds. On February 25, Medline reported its Q4 and full-year 2025 financial results, marking a significant year that included the completion of its initial public offering. For Q4, the company achieved net sales of $7.8 billion, representing a 14.8% increase driven by higher volumes in the Medline Brand and Supply Chain Solutions segments.

However, net income for the quarter fell by 37.7% to $180 million, while Adjusted EBITDA remained nearly flat at $805 million, impacted by higher operating costs, IPO-related expenses, and tariff-related costs of goods sold. The full year results showed a 11.5% increase in net sales to $28.4 billion, supported by $2.4 billion in new customer signings. While net income for the year decreased slightly by 3.6% to $1.2 billion due to investments in headcount and tariffs, Adjusted EBITDA grew by 3.2% to $3.5 billion.

Looking ahead, the CEO emphasized that the transition to a public company has strengthened Medline’s foundation for sustainable long-term growth. The company introduced 2026 guidance, projecting organic sales growth between 8% and 9%. Additionally, Medline Inc. (NASDAQ:MDLN) expects Adjusted EBITDA for 2026 to reach a range of $3.5 billion to $3.6 billion as it continues to utilize its distribution footprint and broad product portfolio.

Photo from Iovance Biotherapeutics website

Medline Inc. (NASDAQ:MDLN) manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the US and internationally. It operates through two segments: Medline Brand and Supply Chain Solutions.